Jimenez offers bouquet to FDA's Hamburg

Novartis ($NVS) CEO Joe Jimenez (photo) is no stranger to the executive Q&A; he's been chatted up by almost every big media outlet there is. However, every once in a while, he drops a bit of new information into his spiel. With Smart Money, he offers mild kudos to Margaret Hamburg's FDA. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.